Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis

Acta Radiologica

Volumn 48, Issue 2, 2007, Pages 145-149

  Moller J M ^a,b   Santoni Rugiu, E ^a   Chabanova, E ^a   Logager V ^a   Hansen, A B ^a   Thomsen, H S ^a  

^a Copenhagen University Hospital ^*  (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abdomen; Bile duct; Liver; MR imaging; Oral contrast agent

Indexed keywords

BIOPSY; COMPUTERIZED TOMOGRAPHY; CONTRAST MEDIA; MEDICAL PROBLEMS; ULTRASONICS;

BILE DUCT; HEPATOCYTES; JAUNDICE; LIVER BIOPSY; RENAL FAILURES;

MAGNETIC RESONANCE IMAGING;

CMC 001; CMC-001; CONTRAST MEDIUM; DIAGNOSTIC AGENT; MANGANESE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ARTICLE; ATROPHY; BIOPSY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; FATALITY; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER FUNCTION TEST; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; MIDDLE AGED;

AMYLOIDOSIS; ATROPHY; BIOPSY; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; CHOLESTASIS, INTRAHEPATIC; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HUMANS; LIVER FUNCTION TESTS; MALE; MANGANESE; MIDDLE AGED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33947176596     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850601128959     Document Type: Article

References (20)

1. Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 2000; 10:1697-702.
2. Bellin MF, Webb JA, Van Der Molen AJ, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR), Safety of MR liver specific contrast media. Eur Radiol 2005;15:1607-14.
3. Benson L, Hemmingsson A, Ericsson A, Jung B, Sperber G, Thuomas KA, et al. Magnetic resonance imaging in primary amyloidosis. Acta Radiol 1987;28: 13-5.
4. Burnett KR, Goldstein EJ, Wolf GL, Sen S, Mamourian AC. The oral administration of MnCl2: a potential alternative to IV injection for tissue contrast enhancement in magnetic resonance imaging. Magn Reson Imaging 1984;2:307-14.
5. Chabanova E, Thomsen HS, Logager V, Moller JM, Brage K, Fogh K, et al. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial. MAGMA 2004;17:28-35.
6. Husby G. Amyloidosis. In: Hansen NE, Haunsø S, Schaffalitzky de Muckadell OB, editors. Medicinsk kompendium. Copenhagen: Nyt Nordisk Forlag; 2004. p. 584-93.
7. Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003;58:610-20.
8. Kitamura Y, Yokomori H. Hepatic amyloidosis manifesting severe intrahepatic cholestasis. Intern Med 2005;44:675-6.
9. Kreft BP, Baba Y, Tanimoto A, Finn JP, Stark DD. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Radiology 1993; 186: 543-8.
10. Looi LM, Sumithran E. Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis. Hum Pathol 1988;19:732-5.
11. Monzawa S, Tsukamoto T, Omata K, Hosoda K, Araki T, Sugimura K. A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur J Radiol 2002;41:237-41.
12. Morana G, Grazioli L, Testoni M, Caccia P, Procacci C. Contrast agents for hepatic magnetic resonance imaging. Top Magn Reson Imaging 2002;13:117-50.
13. Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin Liver Dis 2001;21:195-212.
14. Ohta H, Kokuryu H, Ota T, Tomono N, Shimizu T, Shintaku M, et al. CT, MR imaging, and radionuclide imaging in a patient with hepatic involvement in primary amyloidosis. Clin Nucl Med 1997;22:778-80.
15. Peters RA, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R. Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut 1994;35: 1322-5.
16. Schmiedl UP, Nelson JA, Teng L, Starr F, Malek R, Ho RJ. Magnetic resonance imaging of the hepatobiliary system: intestinal absorption studies of manganese mesoporphyrin. Acad Radiol 1995;2:994-1001.
17. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001;218:27-38.
18. Thomsen HS, Barentsz JO, Burcharth F, Chabanova E, Dekker HM, Moesgaard F, et al. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. Eur Rad 2006 Jun 9 Epub.
19. Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J. Oral manganese for liver imaging at three different field strengths. Acad Radiol 2004; 11: 630-6.
20. Thomsen HS, Svendsen O, Klastrup S. Increased manganese concentration in the liver after oral intake. Acad Radiol 2004; 11:38-44.